Microba Life Sciences (ASX:MAP) Debt-to-EBITDA : -0.07 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Microba Life Sciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Microba Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.87 Mil. Microba Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.51 Mil. Microba Life Sciences's annualized EBITDA for the quarter that ended in Dec. 2023 was A$-20.88 Mil. Microba Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.07.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Microba Life Sciences's Debt-to-EBITDA or its related term are showing as below:

ASX:MAP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.13 Med: -0.12 Max: -0.08
Current: -0.08

During the past 2 years, the highest Debt-to-EBITDA Ratio of Microba Life Sciences was -0.08. The lowest was -0.13. And the median was -0.12.

ASX:MAP's Debt-to-EBITDA is ranked worse than
100% of 104 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.83 vs ASX:MAP: -0.08

Microba Life Sciences Debt-to-EBITDA Historical Data

The historical data trend for Microba Life Sciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microba Life Sciences Debt-to-EBITDA Chart

Microba Life Sciences Annual Data

Trend

Jun22

Jun23

Debt-to-EBITDA

-0.13

-0.10

Microba Life Sciences Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	N/A	N/A	-0.12	-0.09	-0.07

Competitive Comparison of Microba Life Sciences's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Microba Life Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Microba Life Sciences's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Microba Life Sciences's Debt-to-EBITDA falls into.

Microba Life Sciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Microba Life Sciences's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.902	+	0.234)	/	-11.016
	=	-0.10

Microba Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.868	+	0.511)	/	-20.876
	=	-0.07

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

Microba Life Sciences (ASX:MAP) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Microba Life Sciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Microba Life Sciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Microba Life Sciences (ASX:MAP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Microba Life Sciences Ltd (ASX:MAP) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000

Website

https://www.microba.com

Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome which includes delivering gut microbiome testing services globally to consumers, clinicians, and researchers. The company's segment includes Testing Services, and Research and Development.

Microba Life Sciences (ASX:MAP) Headlines

No Headlines